share_log

BRIEF-AIM Immunotech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

reuters ·  Oct 19, 2021 07:25

Oct 19 (Reuters) - AIM ImmunoTech Inc AIM.A :

* AIM IMMUNOTECH SUBMITS IND AND ACCOMPANYING FAST TRACK APPLICATION FOR PHASE 2 TRIAL OF AMPLIGEN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LATE-STAGE PANCREATIC CANCER

Source text for Eikon: ID:nGNEMYnyj Further company coverage: AIM.A

((reuters.briefs@thomsonreuters.com;))

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment